Primate Lentiviral Vpx Commandeers DDB1 to Counteract a Macrophage Restriction

Primate lentiviruses encode four “accessory proteins” including Vif, Vpu, Nef, and Vpr/Vpx. Vif and Vpu counteract the antiviral effects of cellular restrictions to early and late steps in the viral replication cycle. We present evidence that the Vpx proteins of HIV-2/SIVSM promote virus infection by antagonizing an antiviral restriction in macrophages. Fusion of macrophages in which Vpx was essential for virus infection, with COS cells in which Vpx was dispensable for virus infection, generated heterokaryons that supported infection by wild-type SIV but not Vpx-deleted SIV. The restriction potently antagonized infection of macrophages by HIV-1, and expression of Vpx in macrophages in trans overcame the restriction to HIV-1 and SIV infection. Vpx was ubiquitylated and both ubiquitylation and the proteasome regulated the activity of Vpx. The ability of Vpx to counteract the restriction to HIV-1 and SIV infection was dependent upon the HIV-1 Vpr interacting protein, damaged DNA binding protein 1 (DDB1), and DDB1 partially substituted for Vpx when fused to Vpr. Our results indicate that macrophage harbor a potent antiviral restriction and that primate lentiviruses have evolved Vpx to counteract this restriction.

[1]  P. Bieniasz,et al.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu , 2008, Nature.

[2]  Xiao-Fang Yu,et al.  DDB1 and Cul4A Are Required for Human Immunodeficiency Virus Type 1 Vpr-Induced G2 Arrest , 2007, Journal of Virology.

[3]  M. Washburn,et al.  Lentiviral Vpr usurps Cul4–DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle , 2007, Proceedings of the National Academy of Sciences.

[4]  A. Finzi,et al.  HIV-1 Vpr-Mediated G2 Arrest Involves the DDB1-CUL4AVPRBP E3 Ubiquitin Ligase , 2007, PLoS pathogens.

[5]  E. Zimmerman,et al.  HIV-1 Vpr activates the G2 checkpoint through manipulation of the ubiquitin proteasome system , 2007, Virology Journal.

[6]  E. Wiertz,et al.  Ubiquitination of serine, threonine, or lysine residues on the cytoplasmic tail can induce ERAD of MHC-I by viral E3 ligase mK3 , 2007, The Journal of cell biology.

[7]  Jean-Christophe Rain,et al.  HIV1 Vpr Arrests the Cell Cycle by Recruiting DCAF1/VprBP, a Receptor of the Cul4-DDB1 Ubiquitin Ligase , 2007, Cell cycle.

[8]  P. Cascio,et al.  Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. , 2006, Blood.

[9]  T. Hope,et al.  Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  L. McGinnes,et al.  Inhibition of Receptor Binding Stabilizes Newcastle Disease Virus HN and F Protein-Containing Complexes , 2006, Journal of Virology.

[11]  B. Cullen Role and Mechanism of Action of the APOBEC3 Family of Antiretroviral Resistance Factors , 2006, Journal of Virology.

[12]  K. Cadwell,et al.  Ubiquitination on Nonlysine Residues by a Viral E3 Ubiquitin Ligase , 2005, Science.

[13]  J. Garcia,et al.  Inhibition of Lysosome and Proteasome Function Enhances Human Immunodeficiency Virus Type 1 Infection , 2005, Journal of Virology.

[14]  F. Bushman,et al.  Cell Cycle Arrest in G2/M Promotes Early Steps of Infection by Human Immunodeficiency Virus , 2005, Journal of Virology.

[15]  Reuben S. Harris,et al.  Retroviral restriction by APOBEC proteins , 2004, Nature Reviews Immunology.

[16]  M. Carrington Faculty Opinions recommendation of Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. , 2002 .

[17]  M. L. Penn,et al.  HIV-1 Vpr Enhances Viral Burden by Facilitating Infection of Tissue Macrophages but Not Nondividing CD4+ T Cells , 2001, The Journal of experimental medicine.

[18]  D. Kabat,et al.  Cellular and Viral Specificities of Human Immunodeficiency Virus Type 1 Vif Protein , 2000, Journal of Virology.

[19]  Navid Madani,et al.  An Endogenous Inhibitor of Human Immunodeficiency Virus in Human Lymphocytes Is Overcome by the Viral Vif Protein , 1998, Journal of Virology.

[20]  M. Malim,et al.  Evidence for a newly discovered cellular anti-HIV-1 phenotype , 1998, Nature Medicine.

[21]  M. Malim,et al.  HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. , 1998, Science.

[22]  B. Hahn,et al.  Differential association of uracil DNA glycosylase with SIVSM Vpr and Vpx proteins. , 1998, Virology.

[23]  Bertrand Friguet,et al.  Antiviral Activity of the Proteasome on Incoming Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.

[24]  P. Sharp,et al.  Nuclear import and cell cycle arrest functions of the HIV‐1 Vpr protein are encoded by two separate genes in HIV‐2/SIV(SM). , 1996, The EMBO journal.

[25]  F. Rey,et al.  Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme , 1996, Journal of virology.

[26]  D O Morgan,et al.  Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity , 1995, Journal of virology.

[27]  J. Luban,et al.  Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B , 1995, Journal of virology.

[28]  Satoshi Omura,et al.  Degradation of CFTR by the ubiquitin-proteasome pathway , 1995, Cell.

[29]  Meng Chen,et al.  The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle , 1995, Journal of virology.

[30]  M. Emerman,et al.  The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection , 1995, Journal of virology.

[31]  R. Connor,et al.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. , 1995, Virology.

[32]  M. Emerman,et al.  The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Kolson,et al.  Distinct effects in primary macrophages and lymphocytes of the human immunodeficiency virus type 1 accessory genes vpr, vpu, and nef: mutational analysis of a primary HIV-1 isolate. , 1994, Virology.

[34]  L. Ratner,et al.  Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions , 1993, Journal of virology.

[35]  J. Mullins,et al.  Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14 , 1990, Nature.

[36]  J. Sodroski,et al.  Human immunodeficiency virus vpr product is a virion-associated regulatory protein , 1990, Journal of virology.

[37]  L. Hood,et al.  Identification of a novel retroviral gene unique to human immunodeficiency virus type 2 and simian immunodeficiency virus SIVMAC , 1988, Journal of virology.

[38]  K. Überla,et al.  Retrovirology BioMed Central , 2008 .

[39]  L. Van Aelst,et al.  Lentiviral delivery of RNAi in hippocampal neurons. , 2006, Methods in enzymology.

[40]  John L. Sullivan,et al.  Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy , 2000, Nature Medicine.